ClinicalTrials.gg
Sign In

Drug

Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 clinical trials

Also written SYS6043.

studies test it
5
open now
5
in phase 3
1
first study started
2024

Keep track of what changes. Save the Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

SYS6043
4

Combined with it in one product

SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection
1

Studies by the year they started

5 studies that test it; most in 2026 (4)

Studies that test Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043, by start year
YearStudies
20241
20264

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
3
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Hepatocellular
1
Neoplasms
1

Who runs them

Industry 5 · Other 0

CSPC Megalith Biopharmaceutical Co.,Ltd. (4) · Conjupro Biotherapeutics, Inc. (1)

Often tested with

Tested in the same studies.

Bevacizumab (2) · Anti-PD-1/IL-15 Fusion Protein JMT108 (1) · Sintilimab (1)

Studies

Open first, then newest update. How each study uses Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 is read from its arms, and is right about nine times in ten.

Testing it · 5

Given in every arm · 1 — Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 is usual care beside what is tested